Johnson & Johnson

The company requested a comprehensive legal and regulatory overview of domestic and international circulation of medicinal products. Within three years, we provided expert support on regulatory matters related to the circulation of medicines containing narcotic and psychotropic substances, as well as on HIV prevention and treatment policies.

Client’s request

Our results:

Timely adjustments made to client’s strategy.

01

Minimized regulatory risks.

02

Our solution

Key focus areas

01

In 2018, we conducted a comparative legal analysis of regulatory acts in Russia, the EAEU countries, the US, Canada, and the EU.

Comparative Legal Studies

03

In 2020, we provided analytical and GR support to address risks arising from changes in pharmaceutical supply regulation and evolving approaches to the treatment of socially significant diseases.

Analytical and GR support

02

In 2019, we completed an audit of key stakeholder opinions to forecast the implementation of Russia’s HIV policy for 2020–2025.

Stakeholder Opinion Audit

back to cases and clients

Tags

Years: 2018–2020

Industries: #Pharmaceuticals and medical devices #Healthcare

Stakeholders: #Ministry of Health of the Russian Federation #The Government of the Russian Federation # Federal Service for Supervision in Healthcare of the Russian Federation (Roszdravnadzor) #The FMBA of the Russian Federation #Research and expert organizations #Regional authorities

Our toolkit: #Stakeholder mapping #GR communications #Pharmacoeconomics #Regulatory risk assessment #Data collection #Coalitions and alliances #Argumentation and positioning #Legal review #Lobbying #GR consulting #Organization of meetings